Gynecologic Oncology

The FDA has granted an accelerated approval to dostarlimab-gxly for the treatment of adult patients with mismatch repair-deficient recurrent or advanced solid tumors, as determined by an FDA-approved test, who have progressed on or following previous treatment and who have no satisfactory alternative options.

The FDA has granted a fast track designation to IN10018 as a potential therapeutic option for use in patients with platinum-resistant ovarian cancer.

The FDA has accepted a new supplemental biologics license application that is seeking the approval of pembrolizumab for use as a monotherapy in patients with advanced endometrial carcinoma that is microsatellite instability–high or mismatch repair deficient, who have progressed after systemic therapy in any setting and are not eligible for curative surgery or radiation.

The FDA has granted a regular approval to pembrolizumab plus lenvatinib for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high or mismatch repair deficient, who have disease progression after previous systemic therapy in any setting, and who are not candidates for curative surgery or radiation.

Patients with mismatch repair–deficient recurrent or advanced endometrial cancer gained an efficacious and safe treatment option with the addition of dostarlimab-gxly.

Molecular characterization of endometrial tumors has resulted in a boom of investigative efforts aimed at ushering in a new era of tailored therapeutic regimens for patients with these malignancies.

Dr. O’Malley discusses key findings from 6 trials that were presented at the virtual 2021 SGO Annual Meeting on Women’s Cancer.

Novel therapeutic strategies are poised to expand in adjuvant settings for patients with early-stage disease facing recurrence risks in the treatment paradigms for a range of tumor types after positive data from large phase 3 clinical trials were highlighted at the 2021 American Society of Clinical Oncology Annual Meeting

Practice-validating trials in cervical cancer, endometrial cancer, and ovarian cancer were the focus of the 2021 ASCO Annual Meeting in gynecologic oncology, each carrying relevant implications on extended therapy, surveillance, and biomarker testing.

Pembrolizumab plus platinum-based chemotherapy with or without bevacizumab significantly improved overall survival and progression-free survival over the same platinum-based chemotherapy regimen with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer—irrespective of PD-L1 status.

The FDA has granted priority review to the biologics license application for balstilimab for use in the treatment of patients with recurrent or metastatic cervical cancer who experienced disease progression on, or after, chemotherapy.

The antibody-drug conjugate vic-trastuzumab duocarmazine was found to significantly improve progression-free survival over physician’s choice of treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer, meeting the primary end point of the phase 3 TULIP trial.

The combination of pertuzumab and trastuzumab elicited a 37% disease control in patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer.

OncLive sits down with Nicholas J. Vogelzang, MD, and Erin K. Crane, MD, MPH to discuss the biggest abstracts in genitourinary cancers and gynecologic cancers, respectively, at the 2021 ASCO Annual Meeting.

Although prolonged treatment with bevacizumab for up to 30 months is feasible with consistent safety data for patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer, the regimen did not improve survival over the standard 15 month treatment regimen.

Niraparib, when delivered at an individualized starting dose, was found to be well tolerated in patients with platinum-sensitive recurrent ovarian cancer.

Experts give insight on what they are looking forward to in the endometrial cancer space.

Nicoletta Colombo, MD, PhD, reviews surgical advancements in endometrial cancer.

Experts in endometrial cancer comment on novel targets of interest that are currently being investigated.

Maintenance therapy with niraparib significantly improved progression-free survival in patients with BRCA-mutated ovarian cancer, according to results from three phase 3 trials.

Key opinion leaders take a look at the evolving treatment landscape in endometrial cancer, discussing ongoing trials in the space.

Experts discuss the importance of incorporating molecular features into the selection of adjuvant treatment.

Experts in endometrial cancer comment on therapeutic sequencing in endometrial cancer.

The administration of adjuvant carboplatin and paclitaxel following standard cisplatin-based chemoradiation failed to demonstrate an improvement in progression-free survival or overall survival in women with locally advanced cervical cancer, according to findings from the phase 3 OUTBACK trial.

Key opinion leaders emphasize the importance of the management of adverse events in using pembrolizumab and lenvatinib.